Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.

Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN; Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23.

2.

Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses.

Braithwaite D, Walter LC, Izano M, Kerlikowske K.

J Gen Intern Med. 2016 May;31(5):561-72. doi: 10.1007/s11606-015-3580-3. Epub 2016 Jan 29. Review.

3.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA.

Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.

4.

Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis.

Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES.

J Natl Cancer Inst. 2015 Dec 17;108(5). pii: djv372. doi: 10.1093/jnci/djv372. Print 2016 May.

5.

To screen or not to screen for breast cancer? How do modelling studies answer the question?

Koleva-Kolarova RG, Zhan Z, Greuter MJ, Feenstra TL, De Bock GH.

Curr Oncol. 2015 Oct;22(5):e380-2. doi: 10.3747/co.22.2889.

6.

Using Active Learning for Speeding up Calibration in Simulation Models.

Cevik M, Ergun MA, Stout NK, Trentham-Dietz A, Craven M, Alagoz O.

Med Decis Making. 2016 Jul;36(5):581-93. doi: 10.1177/0272989X15611359. Epub 2015 Oct 15.

7.

Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis.

van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ.

J Natl Cancer Inst. 2015 May 6;107(7). pii: djv103. doi: 10.1093/jnci/djv103. Print 2015 Jul.

8.

Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program.

van Ravesteyn NT, van Lier L, Schechter CB, Ekwueme DU, Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Mandelblatt JS, de Koning HJ.

Am J Prev Med. 2015 May;48(5):535-42. doi: 10.1016/j.amepre.2014.11.010.

9.

Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.

Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN.

Ann Intern Med. 2015 Feb 3;162(3):157-66. doi: 10.7326/M14-0692.

10.

Social network effects of nonlifesaving early-stage breast cancer detection on mammography rates.

Nowak SA, Parker AM.

Am J Public Health. 2014 Dec;104(12):2439-44. doi: 10.2105/AJPH.2014.302153. Epub 2014 Oct 16.

11.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289. Print 2014 Nov.

12.

Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.

Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS.

Ann Intern Med. 2014 Jul 15;161(2):104-12. doi: 10.7326/M13-2867.

13.

Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.

Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS.

J Natl Cancer Inst. 2014 May 28;106(6):dju092. doi: 10.1093/jnci/dju092. Print 2014 Jun.

14.

Using Simulation Modeling to Inform Strategies to Reduce Breast Cancer Mortality in Black Women in the District of Columbia.

Near AM, Mandelblatt JS, Schechter CB, Stoto MA.

Epidemiol Res Int. 2012 Apr 26;2012(2012). pii: 241340.

15.

Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention.

Mandelblatt J, van Ravesteyn N, Schechter C, Chang Y, Huang AT, Near AM, de Koning H, Jemal A.

Cancer. 2013 Jul 15;119(14):2541-8. doi: 10.1002/cncr.28087. Epub 2013 Apr 26.

16.

Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality.

Chang Y, Schechter CB, van Ravesteyn NT, Near AM, Heijnsdijk EA, Adams-Campbell L, Levy D, de Koning HJ, Mandelblatt JS.

Breast Cancer Res Treat. 2012 Dec;136(3):823-35. doi: 10.1007/s10549-012-2274-3. Epub 2012 Oct 27.

17.

Computational modeling and multilevel cancer control interventions.

Morrissey JP, Lich KH, Price RA, Mandelblatt J.

J Natl Cancer Inst Monogr. 2012 May;2012(44):56-66. doi: 10.1093/jncimonographs/lgs014.

18.

Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.

van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, Nelson HD, Mandelblatt JS, de Koning HJ.

Ann Intern Med. 2012 May 1;156(9):609-17. doi: 10.7326/0003-4819-156-9-201205010-00002.

19.

The Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy.

Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Nathanson SD, Ambrosone CB, Bovbjerg DH, Mandelblatt JS, Magai C, Tsai WY, Jacobson JS, Hershman DL.

Breast J. 2012 May-Jun;18(3):203-13. doi: 10.1111/j.1524-4741.2012.01240.x. Epub 2012 Apr 5.

20.

Modeling the impact of population screening on breast cancer mortality in the United States.

Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, Feuer EJ.

Breast. 2011 Oct;20 Suppl 3:S75-81. doi: 10.1016/S0960-9776(11)70299-5.

Supplemental Content

Support Center